Literature DB >> 9886082

Possible involvement of interleukin-1 in cyclooxygenase-2 induction after spinal cord injury in rats.

T Tonai1, Y Taketani, N Ueda, T Nishisho, Y Ohmoto, Y Sakata, M Muraguchi, K Wada, S Yamamoto.   

Abstract

A standardized compression injury of rat spinal cord brought about a time-dependent biphasic production of thromboxane A2 (detected as thromboxane B2) and prostaglandin I2 (detected as 6-ketoprostaglandin F1alpha). Thromboxane B2 was predominant during the first 1 h, whereas the 6-ketoprostaglandin F1alpha level exceeded that of thromboxane B2 at 8 h postinjury. As examined by inhibitor experiments and northern blotting, cyclooxygenase-1 was responsible for the first phase, and cyclooxygenase-2 was involved in the second phase. On compression injury the levels of interleukin-1alpha and -1beta detected as mRNA and protein increased and peaked at 2-4 h. Injection of exogenous interleukin-1alpha into the spinal cord resulted in an increase of cyclooxygenase-2 mRNA content and a predominant production of 6-ketoprostaglandin F1alpha resembling the second phase of eicosanoid production. Concomitantly, extravascular migration of polymorphonuclear leukocytes was enhanced after the interleukin-1alpha injection. These cells together with vascular endothelial cells and glial cells were stained positively with an anti-cyclooxygenase-2 antibody. The results suggest that the immediate eicosanoid synthesis after spinal cord injury was due to the constitutive cyclooxygenase-1 and the delayed synthesis of eicosanoids was attributable to the induction of cyclooxygenase-2 mediated by interleukin-1alpha.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9886082     DOI: 10.1046/j.1471-4159.1999.0720302.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  15 in total

1.  Anti-inflammatory effect of the epigallocatechin gallate following spinal cord trauma in rat.

Authors:  Ali Reza Khalatbary; Hassan Ahmadvand
Journal:  Iran Biomed J       Date:  2011

2.  Mitogen-activated protein kinase-activated protein kinase 2 (MK2) contributes to secondary damage after spinal cord injury.

Authors:  Nader Ghasemlou; Ruben Lopez-Vales; Claude Lachance; Thusanth Thuraisingam; Matthias Gaestel; Danuta Radzioch; Samuel David
Journal:  J Neurosci       Date:  2010-10-13       Impact factor: 6.167

Review 3.  Role of secretory phospholipase a(2) in CNS inflammation: implications in traumatic spinal cord injury.

Authors:  W Lee Titsworth; Nai-Kui Liu; Xiao-Ming Xu
Journal:  CNS Neurol Disord Drug Targets       Date:  2008-06       Impact factor: 4.388

4.  Tempol reduces injury area in rat model of spinal cord contusion injury through suppression of iNOS and COX-2 expression.

Authors:  Hong-Hua Quan; Ku-Seong Kang; Yoon-Kyung Sohn; Ming Li
Journal:  Neurol Sci       Date:  2013-01-25       Impact factor: 3.307

5.  Effect of selective inhibition of cyclooxygenase-2 on lipopolysaccharide-induced hyperalgesia.

Authors:  Padi S V Satyanarayana; Naveen K Jain; Sukhjeet Singh; Shrinivas K Kulkarni
Journal:  Inflammopharmacology       Date:  2004       Impact factor: 4.473

6.  Sodium Butyrate Exerts Neuroprotective Effects in Spinal Cord Injury.

Authors:  M Lanza; M Campolo; G Casili; A Filippone; I Paterniti; S Cuzzocrea; Emanuela Esposito
Journal:  Mol Neurobiol       Date:  2018-09-18       Impact factor: 5.590

7.  Differential expression of sPLA2 following spinal cord injury and a functional role for sPLA2-IIA in mediating oligodendrocyte death.

Authors:  W Lee Titsworth; Xiaoxin Cheng; Yan Ke; Lingxiao Deng; Kenneth A Burckardt; Chris Pendleton; Nai-Kui Liu; Hui Shao; Qi-Lin Cao; Xiao-Ming Xu
Journal:  Glia       Date:  2009-11-01       Impact factor: 7.452

8.  Anti-inflammatory effect of oleuropein in experimental rat spinal cord trauma.

Authors:  A R Khalatbary; Gh R Zarrinjoei
Journal:  Iran Red Crescent Med J       Date:  2012-04-01       Impact factor: 0.611

9.  Intervention of electroacupuncture on spinal p38 MAPK/ATF-2/VR-1 pathway in treating inflammatory pain induced by CFA in rats.

Authors:  Jian-Qiao Fang; Jun-Ying Du; Yi Liang; Jun-Fan Fang
Journal:  Mol Pain       Date:  2013-03-22       Impact factor: 3.395

10.  Risk management profile of etoricoxib: an example of personalized medicine.

Authors:  Paola Patrignani; Stefania Tacconelli; Marta L Capone
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.